Premium
Crystallization and preliminary crystallographic analysis of human aquaporin 1 at a resolution of 3.28 Å
Author(s) -
Ruiz Carrillo David,
To Yiu Ying Janet,
Darwis Dina,
Soon Cin Huang,
Cornvik Tobias,
Torres Jaume,
Lescar Julien
Publication year - 2014
Publication title -
acta crystallographica section f
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.572
H-Index - 37
ISSN - 2053-230X
DOI - 10.1107/s2053230x14024558
Subject(s) - tetramer , aquaporin , tetragonal crystal system , crystallization , crystallography , electron crystallography , chemistry , resolution (logic) , aquaporin 1 , crystal structure , diffraction , biochemistry , electron diffraction , physics , water channel , computer science , mechanical engineering , enzyme , organic chemistry , engineering , artificial intelligence , optics , inlet
Aquaporin water channels (AQPs) are found in almost every organism from humans to bacteria. In humans, 13 classes of AQPs control water and glycerol homeostasis. Knockout studies have suggested that modulating the activity of AQPs could be beneficial for the treatment of several pathologies. In particular, aquaporin 1 is a key factor in cell migration and angiogenesis, and constitutes a possible target for anticancer compounds and also for the treatment of glaucoma. Here, a preliminary crystallographic analysis at 3.28 Å resolution of crystals of human aquaporin 1 (hAQP1) obtained from protein expressed in Sf9 insect cells is reported. The crystals belonged to the tetragonal space group I 422, with unit‐cell parameters a = b = 89.28, c = 174.9 Å, and contained one monomer per asymmetric unit. The hAQP1 biological tetramer is generated via the crystallographic fourfold axis. This work extends previous electron crystallographic studies that used material extracted from human red blood cells, in which the resolution was limited to approximately 3.8 Å. It will inform efforts to improve lattice contacts and the diffraction limit for the future structure‐based discovery of specific hAQP1 inhibitors.